P53 gene mutations in acute myeloid leukemia with 17p monosomy.

@article{Fenaux1991P53GM,
  title={P53 gene mutations in acute myeloid leukemia with 17p monosomy.},
  author={Pierre Fenaux and Philippe Jonveaux and Isabelle Quiquandon and Jean Luc La{\"i} and Jean Michel Pignon and Marie Henriette Loucheux‐Lefebvre and Francis Bauters and Roland Berger and Jean Pierre Kerckaert},
  journal={Blood},
  year={1991},
  volume={78 7},
  pages={
          1652-7
        }
}
We looked for mutations of exons 5 to 8 of the P53 gene in 10 patients with acute myeloid leukemia (AML) and 17p monosomy, and 36 patients with AML and no cytogenetic abnormalities of 17p. DNA was analyzed by polymerase chain reaction, single-strand conformation polymorphism analysis, and nucleotide sequencing. Four of the 10 patients with 17p monosomy showed point mutation, single-nucleotide deletion, or insertion in exons 7 or 8. By contrast, only 1 of the 36 patients with AML and no… 

Figures and Tables from this paper

Mutations of the P53 gene in acute myeloid leukaemia
TLDR
A role for the P53 gene mutations in leukaemogenesis in the relatively small number of AML patients in whom they were found was supported, through loss of tumour suppressive activity of both normal P53 alleles, as reported in solid tumours.
Analysis of the p53 gene mutations in acute myelogenous leukemia: The p53 gene mutations associated with a deletion of chromosome 17
TLDR
Findings suggest that the p53 gene mutations might be involved in the progression and prognosis of at least some cases of AML.
Analysis of p53 gene mutations in acute myeloid leukemia
TLDR
The results confirm the relatively low incidence of p53 mutations in AML and further support the evidence that p53 plays a role in leukemogenesis through a recessive mechanism (two‐hit model) of inactivation of tumor suppressor activity.
p16 gene homozygous deletions in acute lymphoblastic leukemia.
TLDR
It is suggested that homozygous deletion of the p16 gene is seen in about 15% of ALL cases, is not restricted to cases with cytogenetically detectable 9p deletion, and could have a pathogenetic role in this malignancy.
P53 gene mutations in acute myelogenous leukaemia
TLDR
The results indicate that functional inactivation of the p53 gene by point mutational change might be one of the mechanisms underlying disease progression of AML.
P73 mutations and expression in adult de novo acute myelogenous leukemia
TLDR
It is suggested that functional p73 mutations in exons 4, 6 and 7 do not occur in most de novo acute myelogenous leukemia patients, and biallelic expression of p73 occurs in normal bone marrows, some AML samples, and specific cell lines.
Genetic analysis of p53 and RB1 tumor-suppressor genes in blast crisis of chronic myeloid leukemia
TLDR
P53 mutations were restricted to one case of myeloid blast crisis, showing a CGC→TGC (Arg→Cys) mutation at codon 283; two additional cases displayed LOH at 17p13 in the absence of p53 mutations, indicating that inactivation of p 53 and RB1 is a rare event in the molecular pathogenesis of CML acute transformation.
p 16 Gene Homozygous Deletions in Acute Lymphoblastic Leukemia
The p16 protein is a cyclin inhibitor encoded by a gene located in 9p21, which may have antioncogenic properties, and is inactivated by homozygous p16 gene deletion or, less often, point mutation in
Frequent p53 gene mutations in blast crisis of chronic myelogenous leukemia, especially in myeloid crisis harboring loss of a chromosome 17p.
We investigated chromosome alterations and mutations of the p53 gene in 118 samples from 92 patients with chronic myelogenous leukemia in various clinical phases, i.e., chronic phase, accelerated
...
...

References

SHOWING 1-10 OF 32 REFERENCES
Mutations of the p53 gene in lymphoid leukemia.
TLDR
Evidence of the possible involvement of p53 gene mutations in lymphoid leukemias studied by reverse transcriptase-polymerase chain reaction, single strand conformation polymorphism analysis, and nucleotide sequencing is shown.
Mutations in the p53 gene in myelodysplastic syndromes.
TLDR
This study focused on the four highly conserved regions of the p53 gene and detected five patients with aberrantly migrating fragments, confirming the putative mutation in each case by direct sequencing analysis.
Rearrangements in the p53 gene in Philadelphia chromosome positive chronic myelogenous leukemia.
TLDR
Molecular structural analysis of the p53 gene in patients with Philadelphia chromosome-positive chronic myelogenous leukemia indicates a significant incidence of gene rearrangements in patients at either accelerated phase or blastic crisis, and suggests that one of the pathways of development of CML to the acute phase is associated with aberrations in the p 53 nuclear oncogene.
Loss of chromosome 17p13 sequences and mutation of p53 in human breast carcinomas.
TLDR
Altered changes to p53, whether loss of one allele or mutation, are by far the most common changes so far detected in primary human breast tumours.
Evidence that p53 behaves as a tumour suppressor gene in sporadic breast tumours.
TLDR
The results are the first to identify mutations in p53 in primary breast tumours by amplified exons 5 and 6 of the human p53 gene from paired samples of tumour and blood DNA and from placental or tonsil DNA of normal controls.
Chromosome 17 deletions and p53 gene mutations in colorectal carcinomas.
TLDR
The data suggest that p53 gene mutations may be involved in colorectal neoplasia, perhaps through inactivation of a tumor suppressor function of the wild-type p53 genes.
p53: a frequent target for genetic abnormalities in lung cancer.
TLDR
These findings, coupled with the previous demonstration of 17p allele loss in lung cancer, strongly implicate p53 as an anti-oncogene whose disruption is involved in the pathogenesis of human lung cancer.
Frequent mutations in the p53 tumor suppressor gene in human leukemia T-cell lines.
TLDR
The data show that at least 6 of 10 leukemic T-cell lines examined may have lost the normal function of a known tumor suppressor gene, suggesting that this class of genes serves a critical role in the generation of fully tumorigenic leukedmic T cells.
Chromosome aberrations and prognostic factors in therapy-related myelodysplasia and acute nonlymphocytic leukemia.
TLDR
The most important predictive factor for a favorable response to intensive antileukemic chemotherapy in overt leukemia was the absence of a preceding myelodysplastic phase.
...
...